Reporter brief
Fisetin to Reduce Senescence and Mobility Impairment in Peripheral Artery Disease: the FIRST Pilot Randomized Trial
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This is a protocol abstract without reported outcomes; no efficacy conclusions can be drawn from it. The small sample size (n=34) means any pilot results would have poor statistical power to detect meaningful treatment effects. The trial does not report whether fisetin actually reduced senescent cell burden or whether any changes in senescent markers correlated with functional improvement.
Study design and sample
Rct; Human.
People with peripheral artery disease (PAD)
- Design
- Rct
- Sample
- 34
- Journal
- Northwestern University
- Published
- Apr 15, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.